Eisai Announces Positive Results of Phase III Trial for Perampanel in Epilepsy

  Tokyo, Aug 24, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today that results of a Phase III study in epilepsy patients with refractory partial seizures demonstrate the clinical benefits of the novel investigational compound E2007 (generic name: perampanel). Discovered and developed by Eisai, perampanel is a first-in-class drug with a unique mechanism that selectively and non-competitively antagonizes AMPA-type glutamate receptors.  

Sydney

  [ Change ]
 
Today

Max: 19°
Shower or two.
Tomorrow

Min: 13°
Max: 20°
Possible shower.
 

Account

Login

To access your account and listings



Remember me
   
   
   
 
 
Find Hunter Valley accommodation online